Aktuelle Therapie des Sneddon-Syndroms[1]

Literatur

• 1 Bokemeyer D, Schmitz U, Kramer H J. Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor.  Kidney Int. 2000;  58 549-558
• 2 Devos J, Bulcke J, Degreef H, Michielsen B. Sneddon’s syndrome: generalized livedo reticularis and cerebrovascular disease. Importance of hemostatic screening.  Dermatology. 1992;  185 296-299
• 3 Dupont S, Fenelon G, Saiag P, Sirmai J. Warfarin in Sneddon’s syndrome.  Neurology. 1996;  46 1781-1782
• 4 Gambichler T. Analoge/digitale Morphometrie befallener Hautflächen.  Zschr Dermatol. 1996;  182 172-174
• 5 Hachulla E, Piette A M, Hatron P Y, Bletry O. Aspirin and antiphospholipid syndrome.  Rev Med Interne. 2000;  21 83-88s
• 6 Hadrava V, Kruppa U, Russo R C, Lacourciere Y, Tremblay J, Hamet P. Vascular smooth muscle cell proliferation and ist therapeutic modulation in hypertension.  Am Heart J. 1991;  122 1198-1203
• 7 Lousa M, Gobernado J M, Pardo A. Fluctuations of international normalized ratio in patients treated with oral warfarin therapy in Sneddon’s syndrome.  Eur J Neurol. 1999;  6 255
• 8 Lousa M, Sastre J L, Cancelas J A, Gobernado J M, Pardo A. Study of antiphospholipid antibodies in a patient with Sneddon’s syndrome and her family.  Stroke. 1994;  25 1071-1074
• 9 Mesa H A, Lang B, Schumacher M, Vaith P, Peter H H. Sneddon’s syndrome and phospholipid antibodies.  Clin Rheumatol. 1993;  12 253-256
• 10 Nguyen L, Ward W F, Tsao C H, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism.  Proc Soc Exp Biol Med. 1994;  205 80-84
• 11 Otani-A, Takagi-H, Oh-H, Suzuma-K, Matsumura-M, Ikeda-E, Honda-Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes.  Invest Ophthalmol Vis Sci. 2000;  41 1192-1199
• 12 Sinzinger H. Inhibition of mitotic and proliferative activity of smooth muscle cells by prostaglandin E1. Heidelberg: Springer In: Sinzinger H, Rogatti W ed.: Prostaglandin E1 in atherosclerosis. 1st ed 1986: 39-48
• 13 Sinzinger H, Virgolini I, Fitscha P. Wirkmechanismen von Prostaglandin E1 bei Atherosklerose. Heidelberg: Springer In: Heidrich H, Böhme H, Rogatti W ed.: Prostaglandin E1-Wirkungen und therapeutische Wirksamkeit. 1st ed 1988: 14-24
• 14 Sitzer M, Sohngen D, Siebler M. et al . Cerebral microembolism in patients with Sneddon’s syndrome.  Arch Neurol. 1995;  52 271-275
• 15 Wang D W, Zhao H Y, Yang S L, Deng Z D. Effects of captopril on platelet cytosolic free Ca2+ concentrations and suppression of cell proliferation in culture.  J Tongji Med Univ. 1993;  13 183-185
• 16 Zelger B, Sepp N, Stockhammer G. et al . Sneddon’s syndrome. A long-term follow-up of 21 patients.  Arch Dermatol. 1994;  130 519-520

Fußnoten

1 Der Beitrag »Aktuelle Diagnostik des Sneddon-Syndroms« ist im vorhergehenden Heft erschienen (Nr. 24)

Korrespondenz